Additionally, the low level of SDF‐1 transcripts in bone marrow mesenchymal stem cells of patients with AML might be disadvantageous on the engraftment after HSCT [30], which was similar with the our result that the expression of CXCL12 in HSCT patients was significantly higher than those in AML‐ND and AML‐PR group, but not healthy controls, indicating that the cytokine microenvironment in AML patients who had reestablished hematopoiesis at least 6 months after allo‐HSCT was similar with the status in healthy population. This evidence concerns the gene CXCL12 and acute myeloid leukemia.